The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2009Optimization of Selective Mu Opioid Receptor Antagonists for the Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
Objective/Rationale:
In Parkinson’s disease, L-DOPA-induced dyskinesias (LID) are therapeutically limiting side effects that occur with long-term L-DOPA treatment, and their presence significantly... -
Rapid Response Innovation Awards, 2009Identification of Nurr1 Agonists for the Treatment of Parkinson's Disease
Objective/Rationale:
Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons, that represents a very promising therapeutic target for... -
Rapid Response Innovation Awards, 2009Isotopic Stabilization of Dietary Polyunsaturated Fatty Acids as a New Treatment Paradigm for Parkinson's Disease: MPTP and Paraquat Pre-clinical Model Feasibility Studies
Objective/Rationale:
Oxidative stress plays a major role in the development of Parkinson’s disease (PD). Essential (available from diet only) polyunsaturated fatty acids (PUFAs) are one of the first... -
Rapid Response Innovation Awards, 2009Targeting Glia in PD with Novel Anti-Inflammatory Therapeutics
Objective/Rationale:
Loss of dopamine-producing neurons in Parkinson’s disease (PD) is accompanied by inflammation in surrounding support cells, called glial cells. This inflammatory state in glial... -
MJFF Research Grant, 2009Parkinson's Disease, Ashkenazi Jews and LRRK2: a consortium proposal
Objective/Rationale:
Mutations in the LRRK2 gene are the most common genetic cause of classic or typical Parkinson’s disease (PD). One mutation, G2019S, is especially frequent in Jewish (about 14%)... -
MJFF Research Grant, 2009Clinicogenetic Studies of LRRK2 G2019S in Tunisia
Objective/Rationale:
Parkinson’s disease (PD) is a prevalent, heterogeneous disorder with a complex, multifactorial etiology. In Tunisia, North Africa, the burden of genetically-defined LRRK2 G2019S...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.